bioRxivMicrobiology
CRISPR screen reveals that EHEC’s T3SS and Shiga toxin rely on shared host factors for infection
A. R. Pacheco, J. E. Lazarus, B. Sit, S. Schmieder, W. Lencer, C. J. Blondel, J. Doench, B. M. Davis, M. K. Waldor
Abstract
Enterohemorrhagic Escherichia coli (EHEC) has two critical virulence factors - a type III secretion system (T3SS) and Shiga toxins (Stx) - that are required for the pathogen to colonize the intestine and cause diarrheal disease. Here, we carried out a genome-wide CRISPR/Cas9 loss-of-function screen to identify host loci that facilitate EHEC infection of intestinal epithelial cells. Many of the guide RNAs identified targeted loci known to be associated with sphingolipid biosynthesis, particularly for production of globotriaosylceramide (Gb3), the Stx receptor. Two loci (TM9SF2 and LAPTM4A) with largely unknown functions were also targeted. Mutations in these loci not only rescued cells from Stx-mediated cell death, but also prevented cytotoxicity associated with the EHEC T3SS. These mutations interfered with early events associated with T3SS and Stx pathogenicity, markedly reducing entry of T3SS effectors into host cells and binding of Stx. The convergence of Stx and T3SS onto overlapping host targets provides guidance for design of new host-directed therapeutic agents to counter EHEC infection.\n\nImportanceEnterohemorrhagic Escherichia coli (EHEC) has two critical virulence factors - a type III secretion system (T3SS) and Shiga toxins (Stx) - that are required for colonizing the intestine and causing diarrheal disease. We screened a genome-wide collection of CRISPR mutants derived from intestinal epithelial cells and identified mutants with enhanced survival following EHEC infection. Many had mutations that disrupted synthesis of a subset of lipids (sphingolipids) that includes the Stx receptor globotriaosylceramide (Gb3), and hence protect against Stx intoxication. Unexpectedly, we found that sphingolipids also mediate early events associated with T3SS pathogenicity. Since antibiotics are contraindicated for the treatment of EHEC, therapeutics targeting sphingolipid biosynthesis are a promising alternative, as they could provide protection against both of the pathogens key virulence factors.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Shiga toxin remodels the intestinal epithelial transcriptional response to Enterohemorrhagic Escherichia coli
A. R. Warr, C. J. Kuehl, M. K. Waldor·bioRxiv·Aug 11, 2020
- In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli
Rajkamal Srivastava, Coral González-Prieto, … Cammie F. Lesser·PNAS NexusPeer-reviewed·Sep 1, 2024
- Identification of translocation inhibitors targeting the type III secretion system of enteropathogenic E. coli
S. Mühlen, V. Zapolskii, … P. Dersch·bioRxiv·May 11, 2021
- Transposon-insertion sequencing screens unveil requirements for EHEC growth and intestinal colonization
A. R. Warr, T. P. Hubbard, … M. K. Waldor·bioRxiv·Feb 27, 2019
- Bacterial outer membrane vesicles provide an alternative pathway for trafficking of type III secreted effectors into epithelial cells
Natalie Sirisaengtaksin, Eloise J. O’Donoghue, … Anne Marie Krachler·bioRxiv·Sep 13, 2018
- Quinoclamine inhibits Shiga toxin production in enterohemorrhagic Escherichia coli
O. Kar, H.-C. Feng, … M. Hashimoto·bioRxiv·Sep 26, 2023